Genetic Medicines
Drive meaningful advancements with groundbreaking genetic medicine technologies
Addressing unmet clinical needs with genetic medicines
Genetic medicine modalities promise to reach intracellular disease targets at the nucleic acid level that are undruggable by conventional modalities. But the success of these therapeutics has been limited by therapeutic efficacy, safety and delivery challenges. Alloy offers foundational technologies and discovery capabilities that address these issues to create best-in-class antisense oligonucleotide (ASO) drug candidates.
ASO
Wide range
Use our Anticlastic™ platform to create and drive successful drug development
AntiClastic ASO format
Developed in collaboration with Sudhir Agrawal, a pioneer of antisense technology, our novel, transiently cyclized format minimizes off-target RNA interactions and mitigates the inflammatory response, thereby improving the therapeutic index.
Integrated workflows
From designing and optimizing novel antisense sequences with our state of the art AI sequence design platform to enhancing existing oligonucleotide leads with improved potency and efficacy, our Anticlastic technology and expertise will accelerate and improve your oligonucleotide pipeline.
Flexible partnering
We have flexible, collaborative partnership models that enable you to access this best-in-class oligonucleotide technology, drive impactful results and shape the future of precision medicine.
Anticlastic™ Platform
Versatile format for wide range of applications
AntiClastic ASOs reflect Alloy Therapeutics’ innovative strategy of engineering of oligonucleotides into a unique spatial conformation. The technology brings together opposite ends of a linear oligonucleotide to create transient, cyclic structures that enhance the potency, safety, and drug-like properties of genetic medicines.
Precise design
Optimal use of 3’ and 5’ ends reduces off-target binding and improves engagement of RNaseH for precise cleavage.
Improved potency
Up to 25-fold improved potency compared to standard gapmer ASO against a wide variety of therapeutic targets.
Better medicines
Reduced engagement of off-target RNA and pattern recognition receptors mitigates the inflammatory response and improves the therapeutic index.
Easily scalable
Manufactured using conventional chemical methods and engineered with building blocks of clinically validated and established ASO modifications.
Fully integrated workflows deliver optimized ASO therapeutics for your disease of interest
Our workflow ensures seamless integration into your research pipeline, featuring AI powered antisense oligonucleotide design, identification and optimization of lead sequences using in vitro and in vivo assays, safety evaluations, and pre-clinical development.
In silico sequence selection
Proprietary ML-based workflow streamlines the designs of ASO therapeutics that are optimized for safety and potency.
Lead identification
In vitro cell line based assays, including transfection, gymnosis, protein kinetics, off-target analysis, and biological safety evaluations.
Lead optimization & development
Improving leads across multiple parameters including sequence selection, chemical modification, in vivo and in vitro evaluation, efficacy, and safety profile.
Candidate nomination
Alloy’s comprehensive data package enables confident selection of your lead and streamlined downstream development.
Genetic Medicines
Scientific Advisory Board
Sudhir Agrawal, D.Phil.
Founder ARNAY Sciences; Affiliate Professor, UMass Chan Medical School
Chair: Alloy Genetic Medicine SAB
Douglas Golenbock, M.D
Professor, UMass Chan Medical School
Neil and Margery Blacklow Chair in Infectious Diseases and Immunology
Frank Slack, PhD
Shields Warren Mallinckrodt Professor, Dept. of Pathology Director of the Institute for RNA Medicine, BIDMC
Malcolm MacCoss, PhD
Bohicket Pharma Consulting LLC
Visiting Professor of Chemistry for Medicine at University of Oxford,
Matthew Might, PhD
Professor, Dept. of Medicine Director, Hugh Kaul Precision Medicine Institute, The University of Alabama at Birmingham
Romesh Subramanian, PhD
Co-founder and former CEO, Dyne Therapeutics
Independent Consultant
Discuss partnering with Alloy
Learn how to get started with our proprietary AntiClastic ASO therapeutic formats.
Resources
